
RPG Life Sciences Limited — Investor Relations & Filings
RPG Life Sciences Limited is an integrated pharmaceutical enterprise engaged in the development, manufacturing, and marketing of a diverse range of generic and branded formulations, as well as Active Pharmaceutical Ingredients (APIs). The company operates across several therapeutic segments, including nephrology, oncology, cardiology, rheumatology, and gastroenterology. It maintains a significant presence in the immunosuppressant market, providing critical medications for transplant recipients. With a focus on research and development, the organization produces complex molecules and finished dosages that cater to both domestic and international healthcare markets. Its manufacturing facilities adhere to stringent global quality standards, enabling the supply of essential medicines to regulated and semi-regulated markets worldwide. The portfolio includes a mix of legacy brands and specialty products designed to address chronic and acute medical conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| The Company informed the Exchange about Transcript of Earnings Call. | 2026-05-08 | English | |
| Analysts/Institutional Investor Meet/Con. Call Updates | 2026-05-08 | English | |
| Updates | 2026-05-06 | English | |
| Analysts/Institutional Investor Meet/Con. Call Updates | 2026-04-30 | English | |
| Copy of Newspaper Publication | 2026-04-30 | English | |
| Investor Presentation | 2026-04-30 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 44723557 | The Company informed the Exchange about Transcript of Earnings Call. | 2026-05-08 | English | ||
| 44217326 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-05-08 | English | ||
| 42174605 | Updates | 2026-05-06 | English | ||
| 42163402 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-04-30 | English | ||
| 42176266 | Copy of Newspaper Publication | 2026-04-30 | English | ||
| 42176454 | Investor Presentation | 2026-04-30 | English | ||
| 42183194 | General Updates | 2026-04-29 | English | ||
| 42183323 | Record Date | 2026-04-29 | English | ||
| 42183374 | Appointment | 2026-04-29 | English | ||
| 42183472 | Press Release | 2026-04-29 | English | ||
| 42183531 | Outcome of Board Meeting | 2026-04-29 | English | ||
| 42183710 | Outcome of Board Meeting | 2026-04-29 | English | ||
| 42162204 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-04-23 | English | ||
| 43866432 | Board Meeting — Board Meeting Intimation | 2026-04-22 | English | ||
| 43866454 | Board Meeting — Financial Results/Dividend | 2026-04-22 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AbbVie Inc.
A research-based biopharmaceutical company developing and m…
|
ABBV | US | Manufacturing |
|
AbCellera Biologics Inc.
Discovers and develops antibody-based therapeutics using a …
|
ABCL | CA | Manufacturing |
|
AbClon Inc.
Develops antibody-based therapeutics using CAR-T, NEST, and…
|
174900 | KR | Manufacturing |
|
ABEONA THERAPEUTICS INC.
A clinical-stage biopharma developing cell and gene therapi…
|
ABEO | US | Manufacturing |
|
ABINGDON HEALTH PLC
A CDMO specializing in lateral flow assays, offering develo…
|
ABDX | GB | Manufacturing |
|
ABIONYX Pharma
Develops biotherapies and drug delivery vectors using apoli…
|
ABNX | FR | Manufacturing |
|
ABIVAX
Clinical-stage biotech developing therapeutics for chronic …
|
ABVX | FR | Manufacturing |
|
Abivax S.A.
Clinical-stage biotech developing miRNA therapeutics for in…
|
ABVX | US | Manufacturing |
|
ABL Diagnostics
Develops molecular diagnostic solutions for managing infect…
|
ABLD | FR | Manufacturing |
|
Abliva
Biopharmaceutical company developing medicines for primary …
|
ABLI | SE | Manufacturing |
RPG Life Sciences Limited via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/60243/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=60243 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=60243 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=60243 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 60243}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for RPG Life Sciences Limited (id: 60243)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.